Stanley Choy

Mr. Stanley Choy is a co-founder of SHY Therapeutics, providing financial and advisory services to early-stage, start-up companies, particularly in strategic planning, operations, business development, and regulatory and government affairs for life sciences companies. He serves as a director and co-chair of BioCT, the bioscience industry association for Connecticut, and is on the Advisory Board of the BioCT Innovation Commons, a biotechnology start-up incubator in northeastern Connecticut. Additionally, he currently serves as Chief Operating Officer for HLK Pharmacin and Chief Financial Officer for Qx Therapeutics.

Previously, Mr. Choy was Vice President of Finance and Administration at Kolltan Pharmaceuticals, where he worked alongside Dr. Hadari and Mr. Schmertzler. Prior to Kolltan, he was the CFO of a leading New York/Boston-based law firm and held several finance positions at Pfizer, where he played a key role in the integration of the Warner Lambert and Pharmacia acquisitions. Mr. Choy began his career with Arthur Andersen and Company.

Mr. Choy is a Certified Public Accountant (CPA) with an MBA in Finance from Syracuse University and a degree in Accounting. He is certified in New York State and a member of the American Institute of CPAs.
Mr. Choy previously served as Vice President, Finance and Administration at Kolltan Pharmaceuticals, where he was a colleague of Dr. Hadari and Mr. Schmertzler. Prior to Kolltan, Mr. Choy was the CFO of a leading New York/Boston based law firm and, prior to that, held several finance positions at Pfizer. He was also instrumental in the integration of the Warner Lambert and Pharmacia acquisitions. Mr. Choy started his career with Arthur Andersen and Company.

Mr. Choy is a CPA and has an MBA in finance from Syracuse University and holds an accounting degree. He is certified in New York State and a member of the American Institute of CPA’s.